1.82
-0.04 (-2.15%)
-0.04 (-2.15%)
Upgrade to Real-Time
Afterhours
Volume | 1,052,385 |
|
|||||
News | - | ||||||
Day High | 1.90 | Low High |
|||||
Day Low | 1.73 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Alaunos Therapeutics Inc | TCRT | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.85 | 1.73 | 1.90 | 1.78 | 1.86 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
5,349 | 1,052,385 | $ 1.82 | $ 1,916,989 | - | 0.4053 - 1.90 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:00:47 | formt | 399 | $ 1.82 | USD |
Alaunos Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 393.03M | 215.95M | 184.60M | $ 398.00k | $ - | -0.38 | -5.30 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | - | 1.70M | 4.70% |
Alaunos Therapeutics News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TCRT Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.58 | 1.90 | 1.52 | 1.74 | 1,837,018 | 0.24 | 15.19% |
1 Month | 1.45 | 1.90 | 1.00 | 1.43 | 1,500,531 | 0.37 | 25.52% |
3 Months | 0.4873 | 1.90 | 0.45 | 0.9536626 | 3,092,441 | 1.33 | 273.49% |
6 Months | 0.92 | 1.90 | 0.4053 | 0.8167695 | 2,685,737 | 0.90 | 97.83% |
1 Year | 0.866 | 1.90 | 0.4053 | 0.8239865 | 2,662,486 | 0.954 | 110.16% |
3 Years | 0.866 | 1.90 | 0.4053 | 0.8239865 | 2,662,486 | 0.954 | 110.16% |
5 Years | 0.866 | 1.90 | 0.4053 | 0.8239865 | 2,662,486 | 0.954 | 110.16% |
Alaunos Therapeutics Description
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens (neoAg) arising from genomic mutations. |